Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results

      - Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56

      - Delivers Full-Year Net Revenues of $45.804 Billion on a GAAP Basis, an Increase of 37.7 Percent on a Reported Basis; Adjusted Net Revenues Were $45.784 Billion

      - Full-Year Global Net Revenues from the Immunology Portfolio Were $22.153 Billion, an Increase of 13.2 Percent on a Reported Basis, or 13.4 Percent on an Operational Basis; U.S. Humira Net Revenues Were $16.112 Billion, an Increase of 8.4 Percent; Internationally, Humira Net Revenues Were $3.720 Billion, a Decrease of 13.6 Percent on a Reported Basis, or 12.5 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.590 Billion; Global Rinvoq Net Revenues Were $731 Million

      - Full-Year Global Net Revenues from the Hematologic Oncology Portfolio Were $6.651 Billion, an Increase of 21.7 Percent on a Reported Basis; Global Imbruvica Net Revenues Were $5.314 Billion, an Increase of 13.7 Percent, with U.S. Net Revenues of $4.305 Billion and International Profit Sharing of $1.009 Billion; Global Venclexta Net Revenues Were $1.337 Billion

      - Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion

      - Full-Year Global Net Revenues from the Neuroscience Portfolio Were $3.496 Billion; Global Botox Therapeutic Net Revenues Were $1.387 Billion; Global Vraylar Net Revenues Were $951 Million

      - Reports Fourth-Quarter Diluted EPS of $0.01 on a GAAP Basis, Inclusive of a Non-cash Charge for Skyrizi Contingent Consideration Revaluation Based on Higher Estimated Future Sales; Adjusted Diluted EPS of $2.92

      - Delivers Fourth-Quarter Net Revenues of $13.858 Billion, an Increase of 59.2 Percent on a GAAP Basis

      - Provides 2021 GAAP Diluted EPS Guidance Range of $6.69 to $6.89; Provides 2021 Adjusted Diluted EPS Guidance Range of $12.32 to $12.52


      News provided by

      AbbVie

      Feb 03, 2021, 07:38 ET

      Share this article

      Share this article


      NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020.

      "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "Based on our broad portfolio of diversified growth assets and the robust momentum of our business, we expect impressive growth again in 2021."

      Fourth-Quarter Results

      • Worldwide net revenues were $13.858 billion, an increase of 59.2 percent on a reported basis, or an increase of 6.8 percent on a comparable operational basis.
      • Global net revenues from the immunology portfolio were $5.958 billion, an increase of 15.3 percent on a reported basis, or 14.8 percent on an operational basis.
        • Global Humira net revenues of $5.152 billion increased 4.8 percent on a reported basis, or 4.4 percent on an operational basis. U.S. Humira net revenues were $4.293 billion, an increase of 8.2 percent. Internationally, Humira net revenues were $859 million, a decrease of 9.4 percent on a reported basis, or 11.4 percent on an operational basis, due to biosimilar competition.
        • Global Skyrizi net revenues were $525 million.
        • Global Rinvoq net revenues were $281 million.
      • Global net revenues from the hematologic oncology portfolio were $1.789 billion, an increase of 15.7 percent on a reported basis, or 15.5 percent on an operational basis.
        • Global Imbruvica net revenues were $1.424 billion, an increase of 9.8 percent, with U.S. net revenues of $1.165 billion and international profit sharing of $259 million.
        • Global Venclexta net revenues were $365 million, an increase of 46.2 percent on a reported basis, or 45.0 percent on an operational basis.
      • Global net revenues from the aesthetics portfolio were $1.142 billion, a decrease of 0.7 percent on a comparable operational basis.
        • Global Botox Cosmetic net revenues were $493 million, an increase of 9.1 percent on a comparable operational basis.
      • Global net revenues from the neuroscience portfolio were $1.389 billion, an increase of over 100.0 percent on a reported basis, or 14.9 percent on a comparable operational basis.
        • Global Botox Therapeutic net revenues were $567 million, a decrease of 1.0 percent on a comparable operational basis.
        • Global Vraylar net revenues were $401 million, an increase of 38.0 percent on a comparable operational basis.
        • Global Ubrelvy net revenues were $65 million.
      • On a GAAP basis, the gross margin ratio in the fourth quarter was 66.2 percent. The adjusted gross margin ratio was 81.8 percent.
      • On a GAAP basis, selling, general and administrative expense was 23.3 percent of net revenues. The adjusted SG&A expense was 22.3 percent of net revenues.
      • On a GAAP basis, research and development expense was 13.6 percent of net revenues. The adjusted R&D expense was 12.6 percent of net revenues, reflecting funding actions supporting all stages of our pipeline.
      • On a GAAP basis, the operating margin in the fourth quarter was 27.1 percent. The adjusted operating margin was 46.9 percent.
      • On a GAAP basis, net interest expense was $618 million.
      • On a GAAP basis, the tax rate in the quarter was 102.5 percent. The adjusted tax rate was 11.6 percent.
      • Diluted EPS in the fourth quarter was $0.01 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $2.92.
      • Recorded a $4.7 billion increase in the Skyrizi contingent consideration liability due to higher estimated future sales driven by stronger market share uptake and favorable clinical trial results as well as lower interest rates.

      Note: "Comparable Operational" comparisons include full-quarter current year and prior year results for Allergan, which was acquired on May 8, 2020, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates. Refer to the Key Product Revenues schedules for further details. "Operational" comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates.

      Recent Events

      • AbbVie announced that the European Commission (EC) has approved Rinvoq (upadacitinib, 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS). Rinvoq is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis (RA), PsA and AS. The EC approval is supported by data from three pivotal clinical studies in PsA and AS where Rinvoq met all primary and key secondary endpoints with a safety profile consistent with that seen in RA.
      • AbbVie announced top-line results from the Phase 3b Heads Up study showing that Rinvoq (30 mg, once daily) achieved superiority to Dupixent (dupilumab, 300 mg, every other week) for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, in adults with moderate to severe atopic dermatitis (AD). Rinvoq also showed superiority versus Dupixent for all ranked secondary endpoints, including early improvements in itch and skin clearance. The safety profile of Rinvoq was consistent with previous AD studies, with no new safety risks observed. Full results from the Heads Up study will be submitted for publication in a peer-reviewed journal.
      • AbbVie announced positive results from the Phase 3 induction study, U-ACHIEVE, which showed Rinvoq (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 8 in adult patients with moderate to severe ulcerative colitis (UC). Additionally, all ranked secondary endpoints, including clinical, endoscopic and histologic outcomes, were met. The safety results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed. U-ACHIEVE is the first of two Phase 3 induction studies to evaluate the safety and efficacy of Rinvoq in adults with moderate to severe UC and full results from the study will be presented at a future medical meeting and submitted for publication in a peer-reviewed journal.
      • AbbVie announced positive top-line results from the Phase 3 ADVANCE and MOTIVATE studies, which evaluated the efficacy and safety of Skyrizi (risankizumab) for induction therapy in adult patients with moderate to severe Crohn's disease (CD). In ADVANCE and MOTIVATE, both doses of Skyrizi (600mg and 1200mg) met the co-primary endpoints of clinical remission and endoscopic response at week 12, demonstrating superiority versus placebo. Additionally, key secondary endpoints showed significant clinical and endoscopic outcomes, with symptom improvement observed as early as week 4. The overall safety results in these studies were generally consistent with the known safety profile of Skyrizi, with no new safety risks observed. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
      • AbbVie announced positive top-line results from the Phase 3 KEEPsAKE-1 and KEEPsAKE-2 studies evaluating Skyrizi (150 mg) in adults with active PsA, with Skyrizi demonstrating strong levels of response on both joint and skin endpoints. In both Phase 3 trials, significantly more patients treated with Skyrizi achieved the primary endpoint of ACR20 response at week 24 versus placebo. Results of ranked secondary endpoints showed significant improvements in skin clearance (as measured by at least a 90 percent improvement in Psoriasis Area Severity Index (PASI 90)), physical function (as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)) and minimal disease activity (MDA) at week 24. The safety results in these studies to-date were generally consistent with the known profile of Skyrizi in psoriasis (PsO) patients. Detailed data from both pivotal studies will be presented at an upcoming medical meeting and we expect to submit our regulatory applications for Skyrizi in PsA in the first half of this year.
      • AbbVie hosted an Immunology Strategic Update event on December 14, 2020 for members of the investment community. The event highlighted AbbVie's immunology leadership, market expectations, strong and growing body of clinical data, innovative pipeline, and strategy to capitalize on a best-in-class immunology portfolio over the long term. As part of the event, AbbVie raised its 2025 risk-adjusted combined sales guidance for Skyrizi and Rinvoq to greater than $15 billion, above previous guidance of greater than $10 billion. Supporting materials from the Immunology Strategic Update, including the event presentation and an archived webcast, can be found on AbbVie's Investor Relations website at investors.abbvie.com.
      • At the virtual American Society of Hematology Annual Meeting and Exposition (ASH), AbbVie presented data from nearly 40 abstracts on 8 investigational and approved products across 11 cancer types, including 10 oral presentations. Key data presentations included new disease-free survival data from the Phase 2 CAPTIVATE study evaluating Imbruvica (ibrutinib) plus Venclexta (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); new extended follow-up data for fixed duration treatment Venclexta in CLL from the Phase 3 Murano and Phase 3 CLL14 studies; results from several long-term follow-up studies evaluating Imbruvica in multiple types of blood cancers; and data from collaborations on pipeline candidates in partnership with Genmab and I-Mab. Venetoclax is being developed by AbbVie and Roche and is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Imbruvica is jointly developed and commercialized with Janssen Biotech, Inc.
      • AbbVie announced that the U.S. Food and Drug Administration (FDA) approved the update of the Imbruvica Prescribing Information to include efficacy and safety data for the combination of Imbruvica with rituximab for the treatment of Waldenström's macroglobulinemia (WM). The update is based on more than 5 years of Phase 3 iNNOVATE final analysis data, which demonstrated Imbruvica plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM. Imbruvica was approved as a monotherapy for WM in 2015 and as a combination therapy with rituximab in 2018 based on the iNNOVATE primary analysis.
      • Allergan Aesthetics announced the launch of CoolSculpting Elite, its next generation fat reduction system with new technology that allows for the treatment of two areas of fat at once and new elite applicators designed for improved fit and comfort. CoolSculpting Elite harnesses proven CoolSculpting technology to target, freeze, and eliminate treated fat cells. CoolSculpting Elite is FDA cleared to treat visible fat bulges in nine areas of the body including the thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), upper arm, and the submental and submandibular areas.
      • Allergan Aesthetics entered into a warrant agreement with Cypris Medical, a privately held medical device company, that provides Allergan Aesthetics the right to acquire Cypris Medical, including the company's Xact device, following the completion of a clinical trial to be initiated in 2021. The Xact device is a minimally-invasive alternative option for performing face and neck lifts and the planned clinical trial will evaluate the safety and effectiveness of Xact in treating midface descent as well as for neck lifts.
      • AbbVie presented results from 16 neurotoxin research abstracts across multiple therapeutic and cosmetic indications at the TOXINS 2021 Virtual Conference. The presentations included new analyses from the CD-PROBE study evaluating sustained efficacy and tolerability of Botox (onabotulinumtoxinA) in patients with cervical dystonia, new analyses from the ASPIRE study on patient adherence to Botox for management of spasticity, data on Botox treatment in adult patients with overactive bladder and in pediatric patients with neurogenic detrusor overactivity, a meta-analysis of immunogenicity rates across 10 therapeutic and aesthetic indications and results from a clinical trial evaluating the safety and pharmacodynamic response with higher doses of Botox on clinician and patient reported outcomes in patients with moderate to severe glabellar lines.
      • At the virtual American Academy of Ophthalmology (AAO) 2020, AbbVie presented new Phase 2 efficacy data for an investigational treatment of presbyopia, new data evaluating the effectiveness of Durysta (bimatoprost implant) and additional analysis of data from Phase 3 ARTEMIS studies that shed light on how glaucoma patients with different characteristics may respond to Durysta.
      • AbbVie recently provided new long-term sales guidance. The company expects continued strong total company sales growth leading up to the U.S. Humira (adalimumab) loss of exclusivity (LOE) in 2023. AbbVie expects total company sales to decline in 2023, following the LOE, with modest top-line growth expected in 2024. The company expects a rapid return to strong top-line growth in 2025, with a high-single digit compound annual growth rate (CAGR) through the remainder of the decade. AbbVie also outlined expectations for high-single digit annual growth for its aesthetics portfolio over the next decade, peak Vraylar (cariprazine) sales approaching $4 billion in current approved indications, peak Ubrelvy (ubrogepant) sales of greater than $1 billion and peak atogepant sales of greater than $1 billion. The company reiterated its expectation for greater than $15 billion of risk-adjusted combined Rinvoq and Skyrizi global sales in 2025.
      • AbbVie and Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets. Under the multi-year collaboration, AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets.
      • AbbVie announced that it will collaborate with 6 nonprofit partners as part of its $50 million investment to support health and education opportunity in underserved Black communities across the U.S. The partners include Direct Relief, University of Chicago Medicine's Urban Health Initiative, National Urban League, Year Up, United Negro College Fund (UNCF) and Providence St. Mel School. Additionally, as part of the announcement, AbbVie expanded its employee matching program to 3:1 for donations to civil rights nonprofits fostering racial equity.

      Full-Year 2021 Outlook

      AbbVie is issuing its GAAP diluted EPS guidance for the full-year 2021 of $6.69 to $6.89. AbbVie expects to deliver adjusted diluted EPS for the full-year 2021 of $12.32 to $12.52. The company's 2021 adjusted diluted EPS guidance excludes $5.63 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

      About AbbVie

      AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

      Conference Call

      AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our fourth-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central time.

      Non-GAAP Financial Results

      Financial results for 2020 and 2019 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. The company's 2021 financial guidance is also being provided on both a reported and a non-GAAP basis.

      Forward-Looking Statements

      Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the failure to realize the expected benefits of AbbVie's acquisition of Allergan or to promptly and effectively integrate Allergan's business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

      AbbVie Inc.

      Key Product Revenues

      Quarter Ended December 31, 2020

      (Unaudited)









      % Change vs. 4Q19


      Net Revenues (in millions)


      Reported


      Comparable Operational a, b


      U.S.


      Int'l.


      Total


      U.S.


      Int'l.


      Total


      U.S.


      Int'l.


      Total

      NET REVENUES

      $10,665


      $3,193


      $13,858


      65.9%


      40.4%


      59.2%


      9.4%


      (1.2)%


      6.8%

      Immunology

      4,988


      970


      5,958


      18.9


      (0.1)


      15.3


      18.9


      (2.5)


      14.8

      Humira

      4,293


      859


      5,152


      8.2


      (9.4)


      4.8


      8.2


      (11.4)


      4.4

      Skyrizi

      451


      74


      525


      >100.0


      >100.0


      >100.0


      >100.0


      >100.0


      >100.0

      Rinvoq

      244


      37


      281


      >100.0


      >100.0


      >100.0


      >100.0


      >100.0


      >100.0



















      Hematologic Oncology

      1,373


      416


      1,789


      11.7


      30.9


      15.7


      11.7


      29.9


      15.5

      Imbruvicac

      1,165


      259


      1,424


      8.6


      15.7


      9.8


      8.6


      15.7


      9.8

      Venclexta

      208


      157


      365


      33.5


      67.3


      46.2


      33.5


      64.1


      45.0



















      Aesthetics

      724


      418


      1,142


      n/m


      n/m


      n/m


      (2.5)


      2.5


      (0.7)

      Botox Cosmetic*

      303


      190


      493


      n/m


      n/m


      n/m


      11.1


      6.0


      9.1

      Juvederm Collection*

      147


      184


      331


      n/m


      n/m


      n/m


      (12.1)


      3.4


      (4.0)

      Other Aesthetics*

      274


      44


      318


      n/m


      n/m


      n/m


      (9.3)


      (13.1)


      (9.8)



















      Neuroscience

      1,188


      201


      1,389


      >100.0


      >100.0


      >100.0


      18.3


      (2.0)


      14.9

      Botox Therapeutic*

      472


      95


      567


      n/m


      n/m


      n/m


      0.3


      (7.1)


      (1.0)

      Vraylar*

      401


      —


      401


      n/m


      n/a


      n/m


      38.0


      n/a


      38.0

      Duodopa

      28


      101


      129


      8.5


      9.6


      9.3


      8.5


      3.6


      4.6

      Ubrelvy*

      65


      —


      65


      n/m


      n/a


      n/m


      n/m


      n/a


      n/m

      Other Neuroscience*

      222


      5


      227


      n/m


      n/m


      n/m


      1.7


      (0.4)


      1.7



















      Eye Care

      625


      302


      927


      n/m


      n/m


      n/m


      2.5


      (4.5)


      0.1

      Lumigan/Ganfort*

      68


      85


      153


      n/m


      n/m


      n/m


      (14.1)


      (13.1)


      (13.5)

      Alphagan/Combigan*

      92


      42


      134


      n/m


      n/m


      n/m


      (1.5)


      —


      (1.1)

      Restasis*

      333


      11


      344


      n/m


      n/m


      n/m


      0.7


      (30.4)


      (1.0)

      Other Eye Care*

      132


      164


      296


      n/m


      n/m


      n/m


      24.4


      2.4


      11.1



















      Women's Health

      249


      7


      256


      >100.0


      >100.0


      >100.0


      (12.5)


      (48.1)


      (14.1)

      Lo Loestrin*

      139


      3


      142


      n/m


      n/m


      n/m


      (13.6)


      (31.7)


      (14.1)

      Orilissa/Oriahnn

      37


      1


      38


      10.0


      41.0


      10.7


      10.0


      41.5


      10.7

      Other Women's Health*

      73


      3


      76


      n/m


      n/m


      n/m


      (18.7)


      (65.0)


      (22.6)



















      Other Key Products

      1,136


      310


      1,446


      16.4


      (15.7)


      7.7


      (6.5)


      (19.5)


      (9.6)

      Mavyret

      220


      261


      481


      (27.8)


      (19.0)


      (23.3)


      (27.8)


      (22.1)


      (24.9)

      Creon

      304


      —


      304


      4.0


      n/a


      4.0


      4.0


      n/a


      4.0

      Lupron

      139


      42


      181


      (19.7)


      (8.4)


      (17.4)


      (19.7)


      (5.8)


      (16.9)

      Linzess/Constella*

      279


      7


      286


      n/m


      n/m


      n/m


      16.1


      6.3


      15.9

      Synthroid

      194


      —


      194


      (5.1)


      n/a


      (5.1)


      (5.1)


      n/a


      (5.1)



      a    

      "Comparable Operational" comparisons include full-quarter current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

      b   

      All historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items.

      c    

      Reflects profit sharing for Imbruvica international revenues.

      *

      Represents product(s) acquired as part of the Allergan acquisition.

      n/a = not applicable

      n/m = not meaningful

      AbbVie Inc.

      Key Product Revenues

      Twelve Months Ended December 31, 2020

      (Unaudited)









      % Change vs. 12M19


      Net Revenues (in millions) a


      Reported


      Comparable Operational b, c


      U.S.


      Int'l.


      Total


      U.S.


      Int'l.


      Total


      U.S.


      Int'l.


      Total

      ADJUSTED NET REVENUES d

      $34,859


      $10,925


      $45,784


      45.8%


      16.7%


      37.6%


      6.7%


      (6.8)%


      3.3%

      Immunology

      18,150


      4,003


      22,153


      19.2


      (7.9)


      13.2


      19.2


      (6.9)


      13.4

      Humira

      16,112


      3,720


      19,832


      8.4


      (13.6)


      3.5


      8.4


      (12.5)


      3.7

      Skyrizi

      1,385


      205


      1,590


      >100.0


      >100.0


      >100.0


      >100.0


      >100.0


      >100.0

      Rinvoq

      653


      78


      731


      >100.0


      >100.0


      >100.0


      >100.0


      >100.0


      >100.0



















      Hematologic Oncology

      5,109


      1,542


      6,651


      17.4


      38.3


      21.7


      17.4


      38.5


      21.7

      Imbruvicae

      4,305


      1,009


      5,314


      12.4


      19.5


      13.7


      12.4


      19.5


      13.7

      Venclexta

      804


      533


      1,337


      54.4


      97.0


      69.0


      54.4


      97.8


      69.3



















      Aesthetics

      1,671


      919


      2,590


      n/m


      n/m


      n/m


      (16.5)


      (17.6)


      (16.9)

      Botox Cosmetic*

      687


      425


      1,112


      n/m


      n/m


      n/m


      (8.8)


      (16.7)


      (12.0)

      Juvederm Collection*

      318


      400


      718


      n/m


      n/m


      n/m


      (27.1)


      (18.2)


      (22.4)

      Other Aesthetics*

      666


      94


      760


      n/m


      n/m


      n/m


      (17.7)


      (19.4)


      (17.9)



















      Neuroscience

      2,862


      634


      3,496


      >100.0


      74.0


      >100.0


      14.0


      (2.7)


      11.1

      Botox Therapeutic*

      1,155


      232


      1,387


      n/m


      n/m


      n/m


      (5.4)


      (11.9)


      (6.6)

      Vraylar*

      951


      —


      951


      n/m


      n/a


      n/m


      57.5


      n/a


      57.5

      Duodopa

      103


      391


      494


      5.9


      7.4


      7.1


      5.9


      6.3


      6.2

      Ubrelvy*

      125


      —


      125


      n/m


      n/a


      n/m


      n/m


      n/a


      n/m

      Other Neuroscience*

      528


      11


      539


      n/m


      n/m


      n/m


      (6.4)


      28.1


      (6.0)



















      Eye Care

      1,448


      736


      2,184


      n/m


      n/m


      n/m


      (0.5)


      (8.8)


      (3.4)

      Lumigan/Ganfort*

      165


      213


      378


      n/m


      n/m


      n/m


      (5.0)


      (8.1)


      (6.8)

      Alphagan/Combigan*

      223


      103


      326


      n/m


      n/m


      n/m


      (6.8)


      (1.1)


      (5.2)

      Restasis*

      755


      32


      787


      n/m


      n/m


      n/m


      (0.8)


      —


      (0.7)

      Other Eye Care*

      305


      388


      693


      n/m


      n/m


      n/m


      9.0


      (11.6)


      (3.6)



















      Women's Health

      648


      25


      673


      >100.0


      >100.0


      >100.0


      (13.1)


      (17.9)


      (13.3)

      Lo Loestrin*

      346


      10


      356


      n/m


      n/m


      n/m


      (14.5)


      0.1


      (14.3)

      Orilissa/Oriahnn

      121


      4


      125


      33.3


      96.1


      34.6


      33.3


      97.7


      34.6

      Other Women's Health*

      181


      11


      192


      n/m


      n/m


      n/m


      (22.4)


      (35.2)


      (23.3)



















      Other Key Products

      3,919


      1,215


      5,134


      (2.5)


      (23.4)


      (8.4)


      (13.6)


      (24.0)


      (16.2)

      Mavyret

      785


      1,045


      1,830


      (46.7)


      (26.4)


      (36.7)


      (46.7)


      (26.8)


      (36.9)

      Creon

      1,114


      —


      1,114


      6.9


      n/a


      6.9


      6.9


      n/a


      6.9

      Lupron

      600


      152


      752


      (16.6)


      (9.1)


      (15.2)


      (16.6)


      (5.4)


      (14.5)

      Linzess/Constella*

      649


      18


      667


      n/m


      n/m


      n/m


      10.2


      16.7


      10.4

      Synthroid

      771


      —


      771


      (1.9)


      n/a


      (1.9)


      (1.9)


      n/a


      (1.9)



      a    

      Net revenues include Allergan product revenues from the date of the acquisition, May 8, 2020, through December 31, 2020.

      b   

      "Comparable Operational" comparisons include full-period current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

      c    

      All historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items.

      d   

      Adjusted net revenues exclude specified items. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Percentage change is calculated using adjusted net revenues.

      e    

      Reflects profit sharing for Imbruvica international revenues.

      *

      Represents product(s) acquired as part of the Allergan acquisition.

      n/a = not applicable

      n/m = not meaningful

      AbbVie Inc.

      Consolidated Statements of Earnings

      Quarter and Twelve Months Ended December 31, 2020 and 2019

      (Unaudited) (In millions, except per share data)



      Fourth Quarter

      Ended December 31


      Twelve Months

      Ended December 31


      2020


      2019


      2020


      2019

      Net revenues

      $

      13,858



      $

      8,704



      $

      45,804



      $

      33,266


      Cost of products sold

      4,684



      2,006



      15,387



      7,439


      Selling, general and administrative

      3,231



      1,951



      11,299



      6,942


      Research and development

      1,890



      1,542



      6,557



      6,407


      Acquired in-process research and development

      300



      139



      1,198



      385


      Other operating income

      —



      (890)



      —



      (890)


      Total operating costs and expenses

      10,105



      4,748



      34,441



      20,283










      Operating earnings

      3,753



      3,956



      11,363



      12,983










      Interest expense, net

      618



      455



      2,280



      1,509


      Net foreign exchange loss

      17



      11



      71



      42


      Other expense, net

      4,625



      416



      5,614



      3,006


      Earnings (loss) before income tax expense

      (1,507)



      3,074



      3,398



      8,426


      Income tax expense (benefit)

      (1,545)



      273



      (1,224)



      544


      Net earnings

      38



      2,801



      4,622



      7,882


      Net earnings attributable to noncontrolling interest

      2



      —



      6



      —


      Net earnings attributable to AbbVie Inc.

      $

      36



      $

      2,801



      $

      4,616



      $

      7,882










      Diluted earnings per share attributable to AbbVie Inc.

      $

      0.01



      $

      1.88



      $

      2.72



      $

      5.28










      Adjusted diluted earnings per sharea

      $

      2.92



      $

      2.21



      $

      10.56



      $

      8.94










      Weighted-average diluted shares outstanding

      1,776



      1,485



      1,673



      1,484




      a  

      Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Weighted-average diluted shares outstanding includes the effect of dilutive securities.

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended December 31, 2020

      (Unaudited) (In millions, except per share data)


      1.     Specified items impacted results as follows:


      4Q20


      Earnings (Loss)


      Diluted


      Pre-tax


      After-taxa


      EPS

      As reported (GAAP)

      $

      (1,507)



      $

      36



      $

      0.01


      Adjusted for specified items:






      Intangible asset amortization

      1,838



      1,444



      0.81


      Acquisition and integration costs

      467



      399



      0.22


      Milestones and other R&D expenses

      48



      39



      0.02


      Acquired IPR&D

      300



      296



      0.16


      Change in fair value of contingent consideration

      4,675



      4,671



      2.63


      Tax audit settlements

      —



      (140)



      (0.08)


      Impacts related to tax law changes

      —



      (1,492)



      (0.84)


      Other

      92



      (28)



      (0.01)


      As adjusted (non-GAAP)

      $

      5,913



      $

      5,225



      $

      2.92



       a Represents net earnings attributable to AbbVie Inc.


      Acquisition and integration costs reflect integration costs and amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition. Milestones and other R&D expenses include milestone payments for previously announced collaborations. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Other primarily includes tax related items and COVID-19 related expenses.


      2.     The impact of the specified items by line item was as follows:


      4Q20


      Cost of

      products
      sold


      SG&A


      R&D


      Acquired

       IPR&D


      Other
      expense,
      net

      As reported (GAAP)

      $

      4,684



      $

      3,231



      $

      1,890



      $

      300



      $

      4,625


      Adjusted for specified items:










      Intangible asset amortization

      (1,838)



      —



      —



      —



      —


      Acquisition and integration costs

      (272)



      (126)



      (69)



      —



      —


      Milestones and other R&D expenses

      —



      —



      (48)



      —



      —


      Acquired IPR&D

      —



      —



      —



      (300)



      —


      Change in fair value of contingent consideration

      —



      —



      —



      —



      (4,675)


      Other

      (51)



      (16)



      (22)



      —



      (3)


      As adjusted (non-GAAP)

      $

      2,523



      $

      3,089



      $

      1,751



      $

      —



      $

      (53)



      3.     The adjusted tax rate for the fourth quarter of 2020 was 11.6 percent, as detailed below:


      4Q20


      Pre-tax earnings
      (loss)


      Income

      taxes


      Tax rate

      As reported (GAAP)

      $

      (1,507)



      $

      (1,545)



      102.5

      %

      Specified items

      7,420



      2,231



      30.1

      %

      As adjusted (non-GAAP)

      $

      5,913



      $

      686



      11.6

      %

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended December 31, 2019

      (Unaudited) (In millions, except per share data)


      1.     Specified items impacted results as follows:


      4Q19


      Earnings


      Diluted


      Pre-tax


      After-taxa


      EPS

      As reported (GAAP)

      $

      3,074



      $

      2,801



      $

      1.88


      Adjusted for specified items:






      Intangible asset amortization

      391



      324



      0.22


      Acquisition related costs

      226



      183



      0.12


      Milestones and other R&D expenses

      217



      193



      0.13


      Acquired IPR&D

      139



      123



      0.08


      Reata divestiture

      (330)



      (297)



      (0.20)


      Litigation matters

      (550)



      (435)



      (0.29)


      Change in fair value of contingent consideration

      438



      438



      0.29


      Restructuring

      19



      15



      0.01


      Tax audit settlement

      —



      (133)



      (0.09)


      Other

      (10)



      82



      0.06


      As adjusted (non-GAAP)

      $

      3,614



      $

      3,294



      $

      2.21



       a Represents net earnings attributable to AbbVie Inc.


      Acquisition related costs reflect transaction and financing costs related to the Allergan acquisition. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Litigation matters includes the settlement of an intellectual property dispute with a third party. Restructuring is primarily associated with streamlining global operations. Other primarily includes the impacts of tax law changes and U.S. tax reform.


      2.     The impact of the specified items by line item was as follows: 


      4Q19


      Cost of

      products
      sold


      SG&A


      R&D


      Acquired

       IPR&D


      Other
      operating
      income


      Interest
      expense,
      net


      Other
      expense,
      net

      As reported (GAAP)

      $

      2,006



      $

      1,951



      $

      1,542



      $

      139



      $

      (890)



      $

      455



      $

      416


      Adjusted for specified items:














      Intangible asset amortization

      (391)



      —



      —



      —



      —



      —



      —


      Acquisition related costs

      —



      (53)



      —



      —



      —



      (173)



      —


      Milestones and other R&D expenses

      —



      —



      (217)



      —



      —



      —



      —


      Acquired IPR&D

      —



      —



      —



      (139)



      —



      —



      —


      Reata divestiture

      —



      —



      —



      —



      330



      —



      —


      Litigation matters

      —



      —



      —



      —



      550



      —



      —


      Change in fair value of contingent consideration

      —



      —



      —



      —



      —



      —



      (438)


      Restructuring

      (10)



      (15)



      6



      —



      —



      —



      —


      Other

      —



      —



      —



      —



      10



      —



      —


      As adjusted (non-GAAP)

      $

      1,605



      $

      1,883



      $

      1,331



      $

      —



      $

      —



      $

      282



      $

      (22)



      3.     The adjusted tax rate for the fourth quarter of 2019 was 8.8 percent, as detailed below:


      4Q19


      Pre-tax earnings


      Income

      taxes


      Tax rate

      As reported (GAAP)

      $

      3,074



      $

      273



      8.9

      %

      Specified items

      540



      47



      8.6

      %

      As adjusted (non-GAAP)

      $

      3,614



      $

      320



      8.8

      %

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Twelve Months Ended December 31, 2020

      (Unaudited) (In millions, except per share data)


      1.     Specified items impacted results as follows:


      12M20


      Earnings


      Diluted


      Pre-tax


      After-taxa


      EPS

      As reported (GAAP)

      $

      3,398



      $

      4,616



      $

      2.72


      Adjusted for specified items:






      Intangible asset amortization

      5,805



      4,805



      2.87


      Acquisition and integration costs

      3,366



      3,023



      1.81


      Milestones and other R&D expenses

      273



      241



      0.14


      Acquired IPR&D

      1,198



      1,194



      0.71


      Change in fair value of contingent consideration

      5,753



      5,749



      3.43


      Tax audit settlements

      —



      (200)



      (0.12)


      Impacts related to tax law changes

      —



      (1,689)



      (1.02)


      Other

      239



      42



      0.02


      As adjusted (non-GAAP)

      $

      20,032



      $

      17,781



      $

      10.56



       a Represents net earnings attributable to AbbVie Inc.


      Acquisition and integration costs reflect transaction and financing costs, compensation expense and other integration costs as well as amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Other primarily includes tax related items and COVID-19 related charitable contributions and expenses.


      2.     The impact of the specified items by line item was as follows: 


      12M20


      Net
      revenues


      Cost of

      products
      sold


      SG&A


      R&D


      Acquired

       IPR&D


      Interest
      expense,
      net


      Net foreign
      exchange
      loss


      Other
      expense,
      net

      As reported (GAAP)

      $

      45,804



      $

      15,387



      $

      11,299



      $

      6,557



      $

      1,198



      $

      2,280



      $

      71



      $

      5,614


      Adjusted for specified items:
















      Intangible asset amortization

      —



      (5,805)



      —



      —



      —



      —



      —



      —


      Acquisition and integration costs

      —



      (1,292)



      (1,416)



      (384)



      —



      (274)



      —



      —


      Milestones and other R&D expenses

      —



      —



      —



      (273)



      —



      —



      —



      —


      Acquired IPR&D

      —



      —



      —



      —



      (1,198)



      —



      —



      —


      Change in fair value of contingent 
           consideration

      —



      —



      —



      —



      —



      —



      —



      (5,753)


      Other

      (20)



      (115)



      (80)



      (70)



      —



      —



      9



      (3)


      As adjusted (non-GAAP)

      $

      45,784



      $

      8,175



      $

      9,803



      $

      5,830



      $

      —



      $

      2,006



      $

      80



      $

      (142)



      3.     The adjusted tax rate for the full-year 2020 was 11.2 percent, as detailed below:


      12M20


      Pre-tax earnings


      Income

      taxes


      Tax rate

      As reported (GAAP)

      $

      3,398



      $

      (1,224)



      (36.0)

      %

      Specified items

      16,634



      3,469



      20.9

      %

      As adjusted (non-GAAP)

      $

      20,032



      $

      2,245



      11.2

      %

      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Twelve Months Ended December 31, 2019

      (Unaudited) (In millions, except per share data)


      1.     Specified items impacted results as follows:


      12M19


      Earnings


      Diluted


      Pre-tax


      After-taxa


      EPS

      As reported (GAAP)

      $

      8,426



      $

      7,882



      $

      5.28


      Adjusted for specified items:






      Intangible asset amortization

      1,553



      1,286



      0.86


      Acquisition related costs

      415



      338



      0.23


      Milestones and other R&D expenses

      312



      288



      0.20


      Acquired IPR&D

      385



      364



      0.25


      Reata divestiture

      (330)



      (297)



      (0.20)


      Litigation matters

      (523)



      (414)



      (0.28)


      Change in fair value of contingent consideration

      3,182



      3,184



      2.14


      Restructuring

      207



      168



      0.10


      Stemcentrx-related impairment

      939



      823



      0.56


      Tax audit settlement

      —



      (400)



      (0.27)


      Other

      10



      102



      0.07


      As adjusted (non-GAAP)

      $

      14,576



      $

      13,324



      $

      8.94



       a Represents net earnings attributable to AbbVie Inc.


      Acquisition related costs reflect transaction and financing costs related to the Allergan acquisition. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Litigation matters includes the settlement of an intellectual property dispute with a third party. Restructuring is primarily associated with streamlining global operations. Stemcentrx-related impairment refers to the net impact of the intangible asset impairment and the related fair value adjustment to contingent consideration liabilities. Other primarily includes the impacts of tax law changes and U.S. tax reform.


      2.     The impact of the specified items by line item was as follows:


      12M19


      Cost of

      products
      sold


      SG&A


      R&D


      Acquired

       IPR&D


      Other
      operating
      income


      Interest
      expense,
      net


      Other
      expense,
      net

      As reported (GAAP)

      $

      7,439



      $

      6,942



      $

      6,407



      $

      385



      $

      (890)



      $

      1,509



      $

      3,006


      Adjusted for specified items:














      Intangible asset amortization

      (1,553)



      —



      —



      —



      —



      —



      —


      Acquisition related costs

      —



      (103)



      —



      —



      —



      (312)



      —


      Milestones and other R&D expenses

      —



      —



      (312)



      —



      —



      —



      —


      Acquired IPR&D

      —



      —



      —



      (385)



      —



      —



      —


      Reata divestiture

      —



      —



      —



      —



      330



      —



      —


      Litigation matters

      —



      (27)



      —



      —



      550



      —



      —


      Change in fair value of contingent consideration

      —



      —



      —



      —



      —



      —



      (3,182)


      Restructuring

      (25)



      (125)



      (57)



      —



      —



      —



      —


      Stemcentrx-related impairment

      —



      —



      (1,030)



      —



      —



      —



      91


      Other

      (1)



      —



      (19)



      —



      10



      —



      —


      As adjusted (non-GAAP)

      $

      5,860



      $

      6,687



      $

      4,989



      $

      —



      $

      —



      $

      1,197



      $

      (85)



      3.     The adjusted tax rate for the full-year 2019 was 8.6 percent, as detailed below:


      12M19


      Pre-tax earnings


      Income

      taxes


      Tax rate

      As reported (GAAP)

      $

      8,426



      $

      544



      6.5

      %

      Specified items

      6,150



      708



      11.5

      %

      As adjusted (non-GAAP)

      $

      14,576



      $

      1,252



      8.6

      %

      SOURCE AbbVie

      Modal title

      Also from this source

      Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

      Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from HARMONY IN DIVERSITY and HALO, two Phase 4 studies of aesthetic...

      Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

      Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

      Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.